Evidence-informed peptide therapy for libido and sexual function in both men and women β prescribed confidentially by Australian doctors.
Sexual dysfunction β reduced libido, difficulty with arousal, or poor sexual function β affects a significant proportion of both men and women, and is often inadequately addressed in conventional medicine. Many existing treatments target peripheral vascular mechanisms (e.g. PDE5 inhibitors for erections) but do not address central desire and arousal.
PT-141 (Bremelanotide) works differently β it acts on the melanocortin system in the brain, directly stimulating neural pathways involved in sexual desire and arousal. This makes it effective for both men and women, and for cases where psychological or central factors are involved.
All consultations for this program are completely confidential. Our doctors approach sexual health with the same clinical care and professionalism as any other area of medicine.
PT-141 is a synthetic analogue of alpha-melanocyte stimulating hormone (Ξ±-MSH). It activates melanocortin receptors (MC3R and MC4R) in the central nervous system β specifically pathways in the hypothalamus involved in regulating sexual desire, arousal, and motivation.
Unlike sildenafil (Viagra) or tadalafil (Cialis), which work peripherally by increasing blood flow, PT-141 addresses sexual function at the neurological level. This makes it effective in cases where desire itself is impaired, and it works in women as well as men.
An approved version (Vyleesi) exists in the United States for female HSDD. In Australia, PT-141 is prescribed as a compounded medicine under TGA prescribing authority.
Your Natura doctor reviews your assessment and health history. If appropriate, a prescription is issued and your medicine dispatched within 48h.
PT-141 is taken as needed β 1β3 hours before anticipated sexual activity. Some patients need 2β3 uses to find their optimal dose and timing.
Your doctor will review your response at follow-up and adjust dosing as needed. Most patients find their optimal protocol within 3β4 uses.
PT-141 is used on an as-needed basis β not daily. Repeat prescriptions are available through follow-up consultations.
Common side effects include transient nausea (usually mild, resolves within 1β2 hours), facial flushing, and occasional headache. These diminish with use and are manageable with dose adjustment.
Check your eligibility and book your telehealth consultation. Completely private and judgement-free.
PT-141 (Bremelanotide) is an unregistered medicine in Australia, prescribed under TGA prescribing authority by AHPRA-registered doctors and compounded by TGO 101-compliant pharmacists. Common side effects include transient nausea, flushing, and headache. Not suitable for patients with uncontrolled hypertension. Individual results may vary. Not suitable for patients under 18.